NeuroOne® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
05 Septiembre 2024 - 5:23PM
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)
(“NeuroOne” or the “Company”), a medical technology company focused
on improving surgical care options and outcomes for patients
suffering from neurological disorders, today announced its upcoming
virtual investor presentation at the H.C. Wainwright 26th Annual
Global Investment Conference being held in-person and virtually on
September 9-11, 2024.
The Company’s virtual presentation by Chief
Operating Officer Chris Volker will be available on demand
beginning at 7:00 a.m. ET on Monday, September 9, 2024, through the
end of the conference. To access the presentation, investors can
register for the conference here. One-on-one
meetings are available to registered investors via the conference
website or by contacting their H.C. Wainwright representative.
About NeuroOne
NeuroOne Medical Technologies Corporation is a
developmental stage company committed to providing minimally
invasive and hi-definition solutions for EEG recording, brain
stimulation and ablation solutions for patients suffering from
epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic
pain due to failed back surgeries and other related neurological
disorders that may improve patient outcomes and reduce procedural
costs. The Company may also pursue applications for other areas
such as depression, mood disorders, pain, incontinence, high blood
pressure, and artificial intelligence. For more information,
visit www.nmtc1.com.
Forward Looking Statements
This press release may include forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Except for statements of historical fact, any
information contained in this press release may be a
forward–looking statement that reflects NeuroOne’s current views
about future events and are subject to known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. In some cases, you can identify
forward–looking statements by the words or phrases "may," "might,"
"will," "could," "would," "should," "expect," "intend," "plan,"
"objective," "anticipate," "believe," "estimate," "predict,"
"project," "potential," "target," "seek," "contemplate," "continue,
"focused on," "committed to" and "ongoing," or the negative of
these terms, or other comparable terminology intended to identify
statements about the future. Forward–looking statements may include
statements regarding the transition of manufacturing from sEEG
diagnostic electrodes to OneRF electrodes, the addition of new
centers for the Company’s limited commercial launch, potential
strategic partnership opportunities, continued development of the
Company's electrode technology program (including our drug delivery
program and spinal cord stimulation program), business strategy,
market size, potential growth opportunities, future operations,
future efficiencies, and other financial and operating information.
Although NeuroOne believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that the partnership with Zimmer Biomet may not
facilitate the commercialization or market acceptance of our
technology; whether due to supply chain disruptions, labor
shortages or otherwise; risks that our technology will not perform
as expected based on results of our pre-clinical and clinical
trials; risks related to uncertainties associated with the
Company's capital requirements to achieve its business objectives
and ability to raise additional funds: the risk that we may not be
able to secure or retain coverage or adequate reimbursement for our
technology; uncertainties inherent in the development process of
our technology; risks related to changes in regulatory requirements
or decisions of regulatory authorities; that we may not have
accurately estimated the size and growth potential of the markets
for our technology; risks relate to clinical trial patient
enrollment and the results of clinical trials; that we may be
unable to protect our intellectual property rights; and other
risks, uncertainties and assumptions, including those described
under the heading "Risk Factors" in our filings with the Securities
and Exchange Commission. These forward–looking statements speak
only as of the date of this press release and NeuroOne undertakes
no obligation to revise or update any forward–looking statements
for any reason, even if new information becomes available in the
future.
“Caution: Federal law restricts this device to
sale by or on the order of a physician”
Contact:800-631-4030ir@nmtc1.com
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024